FIG. 3.

βL treatment ameliorates the metabolic symptoms of DIO mice. A–B: The body weights (A) and the ratios of food intake to body weight (B) of the untreated (□; n = 30), vehicle-treated (▵; n = 42), and βl-treated (▿; n = 48) groups were monitored during the oral administration of 50 mg · kg⁻¹ · day⁻¹ βL for 8 weeks. C: The body weight of the untreated (□; n = 6), pair-fed (▵; n = 8), and 50 mg · kg⁻¹ · day⁻¹ βL-treated (▿; n = 8) groups, were monitored for 8 weeks after oral administration of βL (*P < 0.05; **P < 0.005). D: Representative MRI of the coronal (upper panel) and transverse (lower panel) sections in the four indicated mice groups. DIO mice were orally administered vehicle or 50 mg · kg⁻¹ · day⁻¹ βL for 8 weeks. Lean mice were used as control for a normal fat concentration. E: The sizes of lipid droplets in gonadal fat (GF) were compared between DIO mice treated with vehicle (left) and 50 mg · kg⁻¹ · day⁻¹ βL (right) for 4 weeks. Immunostaining with anti-perilipin antibody (red) was used to measure the size of lipid droplets. F: Oil red O staining (red) in the liver from DIO mice treated with vehicle (upper) or 50 mg · kg⁻¹ · day⁻¹ βL (lower) for 4 weeks was used to evaluate hepatic steatosis. Mice used for all the experiments were male (*P < 0.05; **P < 0.005). (A high-quality digital representation of this figure is available in the online issue.)